Kada Akiko, Fukano Reiji, Mori Tetsuya, Kamei Michi, Tanaka Fumiko, Ueyama Junichi, Sekimizu Masahiro, Osumi Tomoo, Mori Takeshi, Koga Yuhki, Ohki Kentaro, Fujita Naoto, Mitsui Tetsuo, Saito Akiko M, Hashimoto Hiroya, Kobayashi Ryoji
Clinical Research Center, NHO Nagoya Medical Center, Nagoya 460-0001,
Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Acta Med Okayama. 2020 Feb;74(1):89-94. doi: 10.18926/AMO/57959.
No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/m2/day) for five days plus melphalan (70 mg/m2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.
复发性或难治性间变性大细胞淋巴瘤（ALCL）尚无标准治疗方案。本研究是一项多中心、开放标签试验，旨在检验降低强度预处理（RIC）移植对20岁以下复发性或难治性ALCL患者的有效性和安全性。我们将RIC定义为连续五天给予氟达拉滨（30 mg/m²/天）加连续两天给予美法仑（70 mg/m²/天），并进行4 Gy的全身照射，随后进行异基因造血干细胞移植。
